Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554616 | 1.00 | NPC1 (0.52) | NPC1RAB9AMAPTALDH1A1NPSR1 | |
| SCHEMBL11669329 | 0.87 | AKR1C3 (0.49) | NPC1RAB9AMAPTALDH1A1MAPK1 | |
| SCHEMBL1553317 | 0.86 | HPGD (0.43) | NPC1RAB9AMAPTALDH1A1NPSR1 | |
| SCHEMBL1553318 | 0.86 | HPGD (0.43) | NPC1RAB9AMAPTALDH1A1NPSR1 | |
| SCHEMBL1553875 | 0.85 | CYP19A1 (0.50) | NPC1RAB9AMAPTALDH1A1CES2 | |
| SCHEMBL9180325 | 0.85 | CYP19A1 (0.50) | NPC1RAB9AMAPTALDH1A1CES2 | |
| SCHEMBL1553877 | 0.85 | CYP19A1 (0.50) | NPC1RAB9AMAPTALDH1A1CES2 | |
| SCHEMBL1554668 | 0.84 | MAPT (0.43) | RAB9AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1554666 | 0.84 | MAPT (0.43) | RAB9AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23332379 | 0.83 | CES2 (0.54) | NPC1RAB9AMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2512242-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-30 | — | — | EP | disclosed |
| US-9029545-B2 | Thienopyridine NOX2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| EP-2512242-A1 | NOVEL COMPOUNDS | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252805-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| WO-2011075559-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2011-06-23 | — | — | WO | disclosed |
| EP-1383463-B1 | FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN | KING PHARMACEUTICALS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1383463-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7449490-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7101905-B2 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-08-17 | — | — | US | disclosed |
| EP-1383463-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | King Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002083083-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | KING PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252805-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | NPC1 1920/4885RAB9A 2150/4885MAPT 1781/4885 |
| US-20060183921-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | NPC1 931/4885RAB9A 1503/4885MAPT 1176/4885 |
| US-20030073733-A1 | Pharmaceutically active compounds and methods of use | TRPV1, TPMT, ACHE | NPC1 931/4885RAB9A 1503/4885MAPT 1176/4885 |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | NPC1 3650/4885RAB9A 1590/4885MAPT 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.